In a recent government meeting, concerns were raised regarding the injunctive relief measures affecting the distribution of controlled substances in California. A licensed civil engineer and advocate for pain patients highlighted the draconian nature of the relief, which has led to significant shortages of medications in pharmacies. He emphasized that the secret thresholds imposed on pharmacies by distributors create a climate of fear, leading to cautious ordering practices that exacerbate these shortages.

The engineer pointed out that if a pharmacy exceeds its undisclosed order threshold, distributors are mandated to halt all controlled substance orders and report the incident as suspicious to regulatory bodies, including the state Attorney General and the DEA. This process, he argued, is detrimental to patients who require legitimate prescriptions for controlled substances.

Pharmacists and medical professionals echoed these sentiments during the meeting. John Gray, a registered pharmacist, noted that the thresholds often fail to account for unique patient needs, particularly in hospice care, and that the slow adjustment process for these thresholds can leave patients without necessary medications. Dr. Richard Thorpe, an internal medicine physician, expressed agreement with the concerns raised, stating that the injunctive relief is causing widespread harm to patients across California.

Participants urged for a collaborative discussion between the Board of Pharmacy and the Medical Board to address these issues. Suggestions included creating a communication strategy to inform pharmacies about their options for adjusting thresholds and advocating for a more sensible approach to controlled substance management.

The meeting underscored the urgent need for regulatory bodies to reassess the impact of current policies on patient care, as stakeholders called for a more transparent and responsive system that prioritizes patient access to necessary medications.